Ameda Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 02-07-2024
- Paid Up Capital ₹ 2.00 M
as on 02-07-2024
- Company Age 19 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 M
as on 02-07-2024
- Revenue 12.91%
(FY 2019)
- Profit 648.80%
(FY 2019)
- Ebitda 60.79%
(FY 2019)
- Net Worth 6.94%
(FY 2019)
- Total Assets 5.83%
(FY 2019)
About Ameda Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹3.50 M.
Lilesh Soneji and Manorama Soneji serve as directors at the Company.
- CIN/LLPIN
U24230GJ2005PTC046626
- Company No.
046626
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Aug 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Ameda Pharma Private Limited offer?
Ameda Pharma Private Limited offers a wide range of products and services, including Bandages & Dressing Disposables, Bandages, Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream, Cosmetic Raw Material, Cosmetic Ingredients, Antibiotic Injection, Ceftriaxone and Sulbactam Injection, Pharmaceutical Medicine.
Who are the key members and board of directors at Ameda Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lilesh Soneji  | Director | 18-Aug-2006 | Current |
| Manorama Soneji | Additional Director | 22-Mar-2024 | Current |
Financial Performance of Ameda Pharma.
Ameda Pharma Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 12.91% increase. The company also saw a substantial improvement in profitability, with a 648.8% increase in profit. The company's net worth moved up by a moderate rise of 6.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ameda Pharma?
In 2019, Ameda Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 18 Mar 2009 | ₹3.50 M | Open |
How Many Employees Work at Ameda Pharma?
Unlock and access historical data on people associated with Ameda Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ameda Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ameda Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
